Q-omics provides the consensus-scored LINC02620 profile across patient tissues and cancer cell-line models. LINC02620 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, LINC02620 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, LINC02620 RNA expression shows 15,269 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, KIRC, and UVM as cancer lineages where LINC02620 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02620 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02620 survival associations across molecular data types. LINC02620 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02620 RNA expression–survival associations across cancer types. High LINC02620 expression shows unfavorable associations in KICH, KIRP, LIHC and KIRC, but favorable associations in ESCA and TGCT. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for LINC02620 RNA expression.
This table summarizes LINC02620 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02620. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02620 shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in BRCA and UCEC. The KIRC box plot shows higher LINC02620 RNA expression in normal versus tumor tissue (log2 FC = −0.030, t-test p < 0.001).
This table shows molecular features associated with LINC02620 in patient tissues and cancer cell lines. In patient samples, LINC02620 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
